A Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study

0572921 - ÚI 2024 RIV CA eng J - Článek v odborném periodiku
Vlasáková, M. - Mužík, J. - Holubová, A. - Fiala, D. - Arsand, E. - Urbanová, J. - Janíčková Žďárská, D. - Brabec, Marek - Brož, J.
A Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study.
JMIR Formative Research. Roč. 7, č. 1 (2023), č. článku e35064. ISSN 2561-326X
Institucionální podpora: RVO:67985807
Klíčová slova: diabetes mellitus * diabetes * telemedicine * telemedicine system * mobile health * mHealth * telemonitoring * quality of life * telehealth * compensation * evaluation * intervention * feasibility
Obor OECD: Statistics and probability
Impakt faktor: 2.2, rok: 2022
Způsob publikování: Open access
https://dx.doi.org/10.2196/35064

BACKGROUND: Today’s diabetes-oriented telemedicine systems can gather and analyze many parameters like blood glucose levels, carbohydrate intake, insulin doses, and physical activity levels (steps). Information collected can be presented to patients in a variety of graphical outputs. Despite the availability of several technical means, a large percentage of patients do not reach the goals established in their diabetes treatment. OBJECTIVE: The objective of the study was to evaluate the benefits of the Diani telemedicine system for the treatment of patients with type 1 diabetes mellitus. METHODS: Data were collected during a 24-week feasibility study. Patients responded to the World Health Organization Quality of Life – BREF (WHOQOL-BREF) questionnaire and a system evaluation questionnaire. The level of glycated hemoglobin (HbA1c) and the patient’s body weight were measured, and the patient’s use of the telemedicine system and their daily physical activity level were monitored. All data were sent from the patient’s device to the Diani server using a real-time diabetes diary app. Wilcoxon and Friedman tests and the linear mixed effects method were used for data analysis. RESULTS: This study involved 10 patients (men: n=5 - women: n=5), with a mean age of 47.7 (SD 19.3) years, a mean duration of diabetes of 10.5 (SD 8.6) years, and a mean HbA1c value of 59.5 (SD 6.7) mmol/mol. The median number of days the patients used the system was 84. After the intervention, the mean HbA1c decreased by 4.35 mmol/mol (P=.01). The patients spent 18.6 (SD 6.8) minutes on average using the app daily. After the intervention, the number of patients who measured their blood glucose level at least 3 times a day increased by 30%. The graphical visualization of the monitored parameters, automatic transmission of measured data from the glucometer, compatibility, and interconnection of individual devices when entering data were positively evaluated by patients. CONCLUSIONS: The Diani system was found to be beneficial for patients with type 1 diabetes mellitus in terms of managing their disease. Patients perceived it positively, it strengthened their knowledge of diabetes and their understanding of the influences of the measured values on the management of their disease. Its use had a positive effect on the HbA1c level.
Trvalý link: https://hdl.handle.net/11104/0343446